Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Alemtuzumab |
| Trade Name | Campath |
| Synonyms | Lemtrada |
| Drug Descriptions |
Alemtuzumab is a monoclonal antibody which selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells (PMID: 32508818) |
| DrugClasses | |
| CAS Registry Number | 216503-57-0 |
| NCIT ID | C1681 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Alemtuzumab | Alemtuzumab | 0 | 4 |
| Alemtuzumab + Cyclophosphamide + Fludarabine + UCART22 | Alemtuzumab Cyclophosphamide Fludarabine UCART22 | 0 | 0 |
| Alemtuzumab + Cyclophosphamide + Mesna | Alemtuzumab Cyclophosphamide Mesna | 0 | 1 |
| Alemtuzumab + Cyclosporine | Alemtuzumab Cyclosporine | 0 | 1 |
| Alemtuzumab + Fludarabine + Melphalan | Alemtuzumab Fludarabine Melphalan | 0 | 1 |
| Alemtuzumab + Itacitinib | Alemtuzumab Itacitinib | 0 | 1 |
| Alemtuzumab + rhIL-15 | Alemtuzumab rhIL-15 | 0 | 1 |
| Alemtuzumab + Rituximab | Alemtuzumab Rituximab | 2 | 0 |